Key points are not available for this paper at this time.
Until recently, tamoxifen, a nonsteroidal antiestrogen, was the mainstay of endocrine treatment of breast cancer. However, new aromatase inhibitors that are many times more potent and specific than the first such agent, aminoglutethimide, are changing the management of breast cancer in postmenopausal women. This review discusses the role of aromatase inhibitors such as letrozole, anastrozole, and exemestane in the treatment of breast cancer.
Building similarity graph...
Analyzing shared references across papers
Loading...
Ian E. Smith
Mitch Dowsett
New England Journal of Medicine
Institute of Cancer Research
Royal Marsden Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Smith et al. (Wed,) studied this question.
www.synapsesocial.com/papers/6a12fc23c031bb6829a7a7b1 — DOI: https://doi.org/10.1056/nejmra023246